Logo - springer
Slogan - springer

| Clinical Drug Investigation – incl. option to publish open access (Editorial Board)

Clinical Drug Investigation

Clinical Drug Investigation

Editor: Jasbir Singh

ISSN: 1173-2563 (print version)
ISSN: 1179-1918 (electronic version)

Journal no. 40261

Editorial Board:

E. Battegay, University Hospital, Basel, Switzerland

E. Beghi, IRCCS Istitutodi Ricerche Farmacologiche Mario Negri, Milan, Italy

L. Bertilsson, Karolinska University Hospital, Stockholm, Sweden

H. Bhally, Waitemata District Health Board, Auckland, New Zealand

B. Brüggenjürgen, Steinbeis-University, Berlin, Germany

S.G. Carruthers, Private Practice, Lisburn, Northern Ireland

A. Chiricozzi, University of Rome Tor Vergata, Pisa, Italy

E. Christophers, University of Kiel, Kiel, Germany

K. Detyniecki, Yale University School of Medicine, New Haven, CT,USA

M.J. Eadie, University of Queensland, Brisbane, QLD, Australia

D.E. Furst, University of California at Los Angeles, Los Angeles,CA, USA

C.S. Gautam, Government Medical College & Hospital, Chandigarh,India

H. Giamarellou, National and Kapodistrian University of AthensMedicine School, Athens, Greece

S. Goutelle, University Hospitals of Lyon, Lyon, France

Y. Hamamoto, Kansai Electric Power Hospital, Osaka, Japan

P.D. Home, University of Newcastle upon Tyne, Newcastle upon Tyne,England

E. Jouanjus, University of Toulouse, Toulouse, France

N.M. Kaplan, University of Texas Southwestern Medical School, Dallas,TX, USA

T.K.L Kiang, University of Alberta, Edmonton, ALB, Canada

G.L. Kearns, Children's Mercy Hospitals and Clinics, Kansas City, MO,USA

F.K. Knop, Gentofte Hospital, University of Copenhagen, Hellerup,Denmark

C.R. Kumana, University of Hong Kong, Hong Kong, China

A. Lahiri, Cardiac Imaging and Research Department in WellingtonHospital, London,, England

J. Lötsch, JohannWolfgang Goethe-University, Frankfurt, Germany

K. McCormack, McCormack Ltd.,, London, England

G. Maconi, Luigi SaccoUniversity Hospital, Milan, Italy

H.I. Maibach, University of California San Francisco School ofMedicine, San Francisco, CA, USA

A. Marcellusi, University of Rome, Rome, Italy

T.O. Morgan, University of Melbourne, Melbourne, Vic., Australia

G.L. Morris III, Aurora BayCare Medical Center, Milwaukee, WI, USA

F.M. Muggia, NYU Cancer Institute, New York, NY, USA

M. Narukawa, Kitasato University, Tokyo, Japan

N. Pérez Álvarez, Polytechnic University of Catalonia, Barcelona,Spain

E. Perucca, University ofPavia, Pavia, Italy

C.V.S. Ram, Texas Blood Pressure Institute, Dallas, TX, USA

E. Raschi, University of Bologna, Bologna, Italy

G. Sani, Sapienza University, Rome, Italy

S.K. Sarin, Institute of Liver and Billiary Sciences, New Delhi,India

S.C. Schachter, BethIsrael Deaconess Medical Centre, Boston, MA, USA

M. Schmitt-Egenolf, Umeå University, Umeå, Sweden

M.W. Simon, Universityof Kentucky, Lexington, KY, USA

T.L. Skaer, Washington State University, Spokane, WA, USA

C. Staatz, University of Queensland, Woolloongabba, QLD, Australia

A.M. Taburet, HôpitauxUniversitaires Paris Sud, Le Kremlin Bicêtre, France

G. Trifirò, University of Messina, Messina, Italy

P. Tugwell, University of Ottawa, Ottawa, ONT, Canada

D. Veritti, University of Udine, Udine, Italy

F.M.E. Wagenlehner, Pediatric Urology and AndrologyJustus-Liebig-University, Giessen, Germany

M.M. Weinberger, University of Iowa Hospitals, Iowa City, IA, USA

V.T. Wong, Hong Kong University, Hong Kong, China

D. Wright, University of Otago, Dunedin, New Zealand

B. Wu, Shanghai Jiaotong University, Shanghai, China

N.J. Zhang, Seton Hall University, South Orange, NJ, USA

H. Zhao, Beijing Ditan Hospital, Capital Medical University, Beijing,China

Read this Journal on Springerlink

For authors and editors

  • Journal Citation Reports®
    2016 Impact Factor
  • 1.853
  • Aims and Scope

    Aims and Scope


    Clinical Drug Investigation provides rapid publication of original research covering all phases of clinical drug development and therapeutic use of drugs. The Journal includes: 

    • Clinical trials, outcomes research, clinical pharmacoeconomic studies and pharmacoepidemiology studies with a strong link to optimum prescribing practice for a drug or group of drugs.
    • Clinical pharmacodynamic and clinical pharmacokinetic studies with a strong link to clinical practice.
    • Pharmacodynamic and pharmacokinetic studies in healthy volunteers in which significant implications for clinical prescribing are discussed.
    • Studies focusing on the application of drug delivery technology in healthcare.
    • Short communications and case study reports that meet the above criteria will also be considered.

    Articles published in Clinical Drug Investigation may be accompanied by plain language summaries to assist patients, caregivers and others in understanding important medical advances

    All manuscripts are subject to peer review by international experts. Letters to the Editor are welcomed and will be considered for publication.

  • Submit Online
  • Open Choice - Your Way to Open Access
  • Instructions for Authors

    Instructions for Authors


  • Important Information for Authors

    Additional Information for Authors


  • Conflict of Interest form (doc, 84 kB)
  • Copyright Information

    Copyright Information


    Copyright Information

    For Authors

    Submission of a manuscript implies: that the work described has not been published before (except in form of an abstract or as part of a published lecture, review or thesis); that it is not under consideration for publication elsewhere; that its publication has been approved by all co-authors, if any, as well as – tacitly or explicitly – by the responsible authorities at the institution where the work was carried out.

    Author warrants (i) that he/she is the sole owner or has been authorized by any additional copyright owner to assign the right, (ii) that the article does not infringe any third party rights and no license from or payments to a third party is required to publish the article and (iii) that the article has not been previously published or licensed. The author signs for and accepts responsibility for releasing this material on behalf of any and all co-authors. Transfer of copyright to Springer (respective to owner if other than Springer) becomes effective if and when a Copyright Transfer Statement is signed or transferred electronically by the corresponding author. After submission of the Copyright Transfer Statement signed by the corresponding author, changes of authorship or in the order of the authors listed will not be accepted by Springer.

    The copyright to this article, including any graphic elements therein (e.g. illustrations, charts, moving images), is assigned for good and valuable consideration to Springer effective if and when the article is accepted for publication and to the extent assignable if assignability is restricted for by applicable law or regulations (e.g. for U.S. government or crown employees).

    The copyright assignment includes without limitation the exclusive, assignable and sublicensable right, unlimited in time and territory, to reproduce, publish, distribute, transmit, make available and store the article, including abstracts thereof, in all forms of media of expression now known or developed in the future, including pre- and reprints, translations, photographic reproductions and microform. Springer may use the article in whole or in part in electronic form, such as use in databases or data networks for display, print or download to stationary or portable devices. This includes interactive and multimedia use and the right to alter the article to the extent necessary for such use.

    Authors may self-archive the Author's accepted manuscript of their articles on their own websites. Authors may also deposit this version of the article in any repository, provided it is only made publicly available 12 months after official publication or later. He/she may not use the publisher's version (the final article), which is posted on SpringerLink and other Springer websites, for the purpose of self-archiving or deposit. Furthermore, the Author may only post his/her version provided acknowledgement is given to the original source of publication and a link is inserted to the published article on Springer's website. The link must be accompanied by the following text: "The final publication is available at link.springer.com".

    Prior versions of the article published on non-commercial pre-print servers like arXiv.org can remain on these servers and/or can be updated with Author's accepted version. The final published version (in pdf or html/xml format) cannot be used for this purpose. Acknowledgement needs to be given to the final publication and a link must be inserted to the published article on Springer's website, accompanied by the text "The final publication is available at link.springer.com". Author retains the right to use his/her article for his/her further scientific career by including the final published journal article in other publications such as dissertations and postdoctoral qualifications provided acknowledgement is given to the original source of publication.

    Author is requested to use the appropriate DOI for the article. Articles disseminated via link.springer.com are indexed, abstracted and referenced by many abstracting and information services, bibliographic networks, subscription agencies, library networks, and consortia.

    For Readers

    While the advice and information in this journal is believed to be true and accurate at the date of its publication, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may have been made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

    All articles published in this journal are protected by copyright, which covers the exclusive rights to reproduce and distribute the article (e.g., as offprints), as well as all translation rights. No material published in this journal may be reproduced photographically or stored on microfilm, in electronic data bases, video disks, etc., without first obtaining written permission from the publisher (respective the copyright owner if other than Springer). The use of general descriptive names, trade names, trademarks, etc., in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

    Springer has partnered with Copyright Clearance Center's RightsLink service to offer a variety of options for reusing Springer content. For permission to reuse our content please locate the material that you wish to use on link.springer.com or on springerimages.com and click on the permissions link or go to copyright.com, then enter the title of the publication that you wish to use. For assistance in placing a permission request, Copyright Clearance Center can be connected directly via phone: +1-855-239-3415, fax: +1-978-646-8600, or e-mail: info@copyright.com.

    © Springer International Publishing Switzerland

Alerts for this journal


Get the table of contents of every new issue published in Clinical Drug Investigation.

Additional information